A-623

DRUG2 trials

Sponsors

Anthera Pharmaceuticals

Conditions

Systemic Lupus Erythematosus

Phase 2

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

CompletedNCT01162681

Anthera PharmaceuticalsSystemic Lupus Erythematosus

Start: 2010-07-31End: 2012-04-30Updated: 2014-03-04

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

CompletedNCT01305746

Anthera PharmaceuticalsSystemic Lupus Erythematosus

Start: 2011-04-30End: 2013-10-31Updated: 2014-02-13

Related Papers

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

2014-04-19114 citations